MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
FibroGen, Inc (NASDAQ: FGEN)*
Organization & Developments: Fibrogen
Parents
FibroGen, Inc (NASDAQ: FGEN)*
Children
*FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics
*FibroGen’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD).
2019: FibroGen Overcomes Safety Hurdle; Clear Path Towards FDA Approval For CKD Patientsseekingalpha.com
2019: FibroGen: Every Chance Of Success Despite Seemingly High Valuation_seekingalpha.com
2021: Fathoming The FDA Decision On FibroGen
2021: FibroGen admits to messing with roxadustat safety data, upending hopes for the AZ-partnered anemia drug
2021: FibroGen's Cardiovascular Data Mess
2021: UPDATED: Safety concerns push FDA adcomm to vote overwhelmingly against approval for FibroGen anemia drug
2022: FibroGen: Growth Prospects Are Not Worth Current Valuations_ seekingalpha.com
2024: FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation
Jumps
*Key People: Fibrogen
Finance & Acquisitions: Fibrogen